The decision to drop the oral ROR gamma inverse agonist – also known as ABBV-157 – came after analysis of a recently concluded nonclinical toxicology study, according to an Inventiva statement, in which the company said it does not expect the move to have any impact on its cash position.
Inventiva has been working with AbbVie on ROR gamma inverse agonists since 2012, and all seemed to be well when the biotech earned a €4 million milestone payment from its partner earlier this year, following the start of a phase 2b trial of cedirogant that aimed to enrol 200 patients with moderate to severe psoriasis.
